Kisqali
NICE Backs Novartis' Kisqali, Aromatase Inhibitor for Certain Breast Cancer Patients
The draft guidance makes the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.
UK's MHRA Approves Kisqali, Aromatase Inhibitor in Early-Stage Breast Cancer
The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.
Jul 18, 2024
May 21, 2024